Efficacy and Safety of Rituximab in Biologic-Naive Patients with Rheumatoid Arthritis vs Anti-Tnf Therapy Failure

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
• Anti-tumor necrosis factor-alpha (anti-TNFα) therapies are common RA treatments, but some patients are naïve or inadequate responders.
• Anti-CD20 therapy, such as rituximab (RTX), offers an alternative treatment option for RA.

Purpose of the Study:

• To compare the efficacy of rituximab (RTX) in rheumatoid arthritis (RA) patients.
• To evaluate RTX in anti-TNFα-naïve patients (Group 1) versus inadequate responders to anti-TNFα therapy (Group 2).

Main Methods:

• Retrospective analysis of 25 RA patients treated with RTX.
• Patients were categorized into anti-TNFα-naïve (n=13) or anti-TNFα-experienced (n=12) groups.
• Efficacy assessed by Disease Activity Score 28 (DAS28), acute phase reactants, and Health Assessment Questionnaire (HAQ) over a mean 6-month follow-up.

Main Results:

• Both groups showed clinical improvement and decreased acute phase reactants.
• Remission (DAS28) was achieved faster in the biologic-naïve group (Group 1) compared to the anti-TNFα-experienced group (Group 2).
• Severe herpes virus infections were more frequent in Group 2.

Conclusions:

• Rituximab is effective in both RA patient populations, achieving clinical remission.
• Disease duration and higher HAQ scores in the anti-TNFα-experienced group contributed to delayed remission.
• Biologic-naïve patients experienced faster remission and potentially fewer severe infections with RTX treatment.